Five-year View
In 5 years' time, this author would expect further studies directed at unrevealing the molecular basis of reactive hyperplasia, atypical lymphoid proliferations and lymphomas. There will be more reliable criteria to define benign, atypical (premalignant, borderline, precursor) and malignant lymphoproliferative disorders. These future criteria will help identify patients with atypical lymphoid proliferations at risk of developing lymphomas.
Expert Rev Hematol. 2013;6(2):139-153. © 2013 Expert Reviews Ltd.
Comments